NVCR Fundamental Analysis - NOVOCURE LTD

Name: NOVOCURE LTD (NVCR) Stock
Brand: NOVOCURE LTD
Rating: 3.5 (3 reviews)

Fundamental Rating

NVCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. NVCR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NVCR is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NVCR has reported negative net income.

NVCR had a negative operating cash flow in the past year.

NVCR had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.

1.2 Ratios

NVCR has a Return On Assets (-13.05%) which is comparable to the rest of the industry.

With a Return On Equity value of -52.05%, NVCR perfoms like the industry average, outperforming 49.74% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-13.05%
ROE	-52.05%
ROIC	N/A

ROA(3y)-13.14%

ROA(5y)-8.53%

ROE(3y)-41.63%

ROE(5y)-26.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 75.57%, NVCR belongs to the top of the industry, outperforming 87.30% of the companies in the same industry.

In the last couple of years the Gross Margin of NVCR has remained more or less at the same level.

NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	75.57%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.51%

GM growth 5Y0.68%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NVCR has more shares outstanding

The number of shares outstanding for NVCR has been increased compared to 5 years ago.

Compared to 1 year ago, NVCR has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.13, we must say that NVCR is in the distress zone and has some risk of bankruptcy.

NVCR has a Altman-Z score (-0.13) which is in line with its industry peers.

A Debt/Equity ratio of 2.21 is on the high side and indicates that NVCR has dependencies on debt financing.

NVCR's Debt to Equity ratio of 2.21 is on the low side compared to the rest of the industry. NVCR is outperformed by 84.13% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.21
Debt/FCF	N/A
Altman-Z	-0.13

ROIC/WACCN/A

WACC6.24%

2.3 Liquidity

NVCR has a Current Ratio of 1.55. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.55, NVCR is not doing good in the industry: 72.49% of the companies in the same industry are doing better.

NVCR has a Quick Ratio of 1.50. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.

NVCR has a Quick ratio (1.50) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	1.55
Quick Ratio	1.5

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NVCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.00%.

The Revenue has grown by 11.17% in the past year. This is quite good.

The Revenue has been growing by 11.49% on average over the past years. This is quite good.

EPS 1Y (TTM)-15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-17.86%

Revenue 1Y (TTM)11.17%

Revenue growth 3Y4.2%

Revenue growth 5Y11.49%

Sales Q2Q%7.81%

3.2 Future

The Earnings Per Share is expected to grow by 20.33% on average over the next years. This is a very strong growth

Based on estimates for the next years, NVCR will show a quite strong growth in Revenue. The Revenue will grow by 19.52% on average per year.

EPS Next Y8.25%

EPS Next 2Y1.15%

EPS Next 3Y9.33%

EPS Next 5Y20.33%

Revenue Next Year8.49%

Revenue Next 2Y7.09%

Revenue Next 3Y9.85%

Revenue Next 5Y19.52%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y1.15%

EPS Next 3Y9.33%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NVCR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVOCURE LTD

NASDAQ:NVCR (11/14/2025, 8:10:37 PM)

After market: 11.51 +0.19 (+1.68%)

11.32

-0.06 (-0.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)10-30 2025-10-30/bmo

Earnings (Next)N/A N/A

Inst Owners87.05%

Inst Owner Change-3.01%

Ins Owners2.83%

Ins Owner Change9.64%

Market Cap1.27B

Revenue(TTM)642.27M

Net Income(TTM)-177.65M

Analysts80

Price Target27.48 (142.76%)

Short Float %5.22%

Short Ratio3.44

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)15.64%

Min EPS beat(2)8.12%

Max EPS beat(2)23.15%

EPS beat(4)3

Avg EPS beat(4)-2.03%

Min EPS beat(4)-73.92%

Max EPS beat(4)34.54%

EPS beat(8)7

Avg EPS beat(8)8.46%

EPS beat(12)8

Avg EPS beat(12)0.73%

EPS beat(16)10

Avg EPS beat(16)-6.5%

Revenue beat(2)2

Avg Revenue beat(2)1.97%

Min Revenue beat(2)0.96%

Max Revenue beat(2)2.98%

Revenue beat(4)4

Avg Revenue beat(4)1.94%

Min Revenue beat(4)0.18%

Max Revenue beat(4)3.65%

Revenue beat(8)7

Avg Revenue beat(8)3.15%

Revenue beat(12)7

Avg Revenue beat(12)1.16%

Revenue beat(16)9

Avg Revenue beat(16)0.67%

PT rev (1m)-2.05%

PT rev (3m)-2.05%

EPS NQ rev (1m)20.19%

EPS NQ rev (3m)20.19%

EPS NY rev (1m)11.21%

EPS NY rev (3m)14.44%

Revenue NQ rev (1m)5.52%

Revenue NQ rev (3m)6.74%

Revenue NY rev (1m)2.68%

Revenue NY rev (3m)3.19%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.97
P/FCF	N/A
P/OCF	N/A
P/B	3.71
P/tB	3.71
EV/EBITDA	N/A

EPS(TTM)-1.61

EYN/A

EPS(NY)-1.52

Fwd EYN/A

FCF(TTM)-0.58

FCFYN/A

OCF(TTM)-0.31

OCFYN/A

SpS5.74

BVpS3.05

TBVpS3.05

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-13.05%
ROE	-52.05%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	75.57%
FCFM	N/A

ROA(3y)-13.14%

ROA(5y)-8.53%

ROE(3y)-41.63%

ROE(5y)-26.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.51%

GM growth 5Y0.68%

F-Score2

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	2.21
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	226.76%
Cap/Sales	4.78%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.55
Quick Ratio	1.5
Altman-Z	-0.13

F-Score2

WACC6.24%

ROIC/WACCN/A

Cap/Depr(3y)276.52%

Cap/Depr(5y)245.8%

Cap/Sales(3y)5.46%

Cap/Sales(5y)4.78%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-17.86%

EPS Next Y8.25%

EPS Next 2Y1.15%

EPS Next 3Y9.33%

EPS Next 5Y20.33%

Revenue 1Y (TTM)11.17%

Revenue growth 3Y4.2%

Revenue growth 5Y11.49%

Sales Q2Q%7.81%

Revenue Next Year8.49%

Revenue Next 2Y7.09%

Revenue Next 3Y9.85%

Revenue Next 5Y19.52%

EBIT growth 1Y-10.33%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year61.72%

EBIT Next 3Y28.16%

EBIT Next 5Y42.57%

FCF growth 1Y26.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y44.83%

OCF growth 3YN/A

OCF growth 5YN/A

NOVOCURE LTD / NVCR FAQ

What is the fundamental rating for NVCR stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVCR.

What is the valuation status for NVCR stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVOCURE LTD (NVCR). This can be considered as Overvalued.

Can you provide the profitability details for NOVOCURE LTD?

NOVOCURE LTD (NVCR) has a profitability rating of 2 / 10.

NOVOCURE LTD (NVCR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NOVOCURE LTD / NVCR FAQ

What is the fundamental rating for NVCR stock?

What is the valuation status for NVCR stock?

Can you provide the profitability details for NOVOCURE LTD?